• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

September

home / publications / evidence-based-oncology / 2012-2-vol18-n4
Site Logo

Study Supports Feasibility of Routine Molecular Screening of NSCLC in Community Setting

Ben Leach
September 21st 2012
ArticleEvidence-Based Oncology

Site Logo

Crizotinib Active in ALK-Positive Pediatric Cancer

Silas Inman
September 20th 2012
ArticleEvidence-Based Oncology

Site Logo

Oncology Leaders Praise Health Law Ruling-With Caveats

Beth Fand Incollingo
September 20th 2012
ArticleEvidence-Based Oncology

Site Logo

How Can We Get Better Value in End-of-Life Care?

Stanton R. Mehr
September 20th 2012
ArticleEvidence-Based Oncology

Site Logo

Down the Road for Breast Cancer

Michael Marlan Mohundro, PharmD;Brice Labruzzo Mohundro, PharmD
September 20th 2012
ArticleEvidence-Based Oncology

Targeted Therapies to Further Improve Outcomes

Site Logo

How Payers and Oncologists Really Feel About Oncology Pathways

Kim Farina, PhD
September 20th 2012
ArticleEvidence-Based Oncology

Site Logo

Partnering With a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice's Experience

Linda D. Bosserman, MD, FACP;Diana Verrilli;Wendy McNatt
September 20th 2012
ArticleEvidence-Based Oncology

Site Logo

Oncology Patient-Centered Medical Home

John D. Sprandio, MD, FACP
September 20th 2012
ArticleEvidence-Based Oncology

Site Logo

Medical Drug Benefit Management in the Pathway Era

Kim Farina, PhD
September 20th 2012
ArticleEvidence-Based Oncology

Site Logo

Rationalizing Treatment and Coverage Decisions With Predictive Biomarkers

Kim Farina, PhD
September 18th 2012
ArticleEvidence-Based Oncology

Site Logo

Implementation of Cancer Clinical Care Pathways

Bruce A. Feinberg, DO;James Lang, PharmD, MBA;James Grzegorczyk, MS, RPh;Donna Stark, RPh, MBA;Thomas Rybarczyk, RN, BSN;Thomas Leyden, MBA;Joseph Cooper;Thomas Ruane, MD;Scott Milligan, PhD
September 18th 2012
ArticleEvidence-Based Oncology

Site Logo

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

September 18th 2012
ArticleEvidence-Based Oncology

Site Logo

The Keys to Obtaining Best Value in Non-Small Cell Lung Cancer

Marj P. Zimmerman, MS, BSPharm, RPh;Stanton R. Mehr
September 18th 2012
ArticleEvidence-Based Oncology

Site Logo

Achieving Quality and Containing Cost Through Oncology Pharmacy Management

Kim Farina, PhD
September 17th 2012
ArticleEvidence-Based Oncology

Site Logo

Treatment and Cost Implications of Pertuzumab

September 17th 2012
ArticleEvidence-Based Oncology

Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.

Site Logo

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned;funded by Eisai Inc.
August 17th 2012
ArticleEvidence-Based Oncology

© 2023 MJH Life Sciences
AJMC®
All rights reserved.